Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

Davis, M.J. et al. RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc. Natl. Acad. Sci. USA 110, 912–917 (2013).

Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251–263 (2012).

Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006–1014 (2012).

Gold, H.L. et al. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Mol. Cancer Res. 12, 433–439 (2014).

Hammond, D. et al. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J. Cell Sci. 126, 3429–3440 (2013).

Prickett, T.D. et al. Exon capture analysis of G protein–coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119–1126 (2011).

Stark, M.S. et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165–169 (2012).

Huang, F.W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013).

Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961 (2013).

Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933–936 (2013).

Harbour, J.W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010).

Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).

Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).

Guen, V.J. et al. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc. Natl. Acad. Sci. USA 110, 19525–19530 (2013).

Chou, C.H. et al. GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle 11, 532–542 (2012).

Gartner, J.J. et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl. Acad. Sci. USA 110, 13481–13486 (2013).

Zang, Z.J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570–574 (2012).

McHugh, J.B., Fullen, D.R., Ma, L., Kleer, C.G. & Su, L.D. Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 34, 597–600 (2007).

Dillon, S.C., Zhang, X., Trievel, R.C. & Cheng, X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6, 227 (2005).

Duns, G. et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70, 4287–4291 (2010).

Wei, X. et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442–446 (2011).

Wu, Q. et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 5, 637–645 (2013).

Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).

Jin, G. et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res. 73, 496–501 (2013).

Yarwood, S., Bouyoucef-Cherchalli, D., Cullen, P.J. & Kupzig, S. The GAP1 family of GTPase-activating proteins: spatial and temporal regulators of small GTPase signalling. Biochem. Soc. Trans. 34, 846–850 (2006).

Chen, P.C. et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc. Natl. Acad. Sci. USA 111, 11473–11478 (2014).

Ratner, N. & Miller, S.J.A. RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290–301 (2015).

Kontaridis, M.I., Swanson, K.D., David, F.S., Barford, D. & Neel, B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281, 6785–6792 (2006).

Tartaglia, M. et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279–290 (2006).

Lepri, F. et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum. Mutat. 32, 760–772 (2011).

Tartaglia, M. et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet. 39, 75–79 (2007).

Roberts, A.E. et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet. 39, 70–74 (2007).

Pandit, B. et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 39, 1007–1012 (2007).

Stowe, I.B. et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 26, 1421–1426 (2012).

Brems, H. et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum. Mutat. 33, 1538–1546 (2012).

Ostman, A., Hellberg, C. & Bohmer, F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307–320 (2006).

Ko, J.M., Kim, J.M., Kim, G.H. & Yoo, H.W. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J. Hum. Genet. 53, 999–1006 (2008).

Tanoue, T., Adachi, M., Moriguchi, T. & Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2, 110–116 (2000).

Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901–5911 (2010).

Johnson, D.B. et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol. 32, 3697–3704 (2014).

Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

Whittaker, S.R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350–362 (2013).

Nissan, M.H. et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74, 2340–2350 (2014).

Ranzani, M. et al. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res. 28, 117–119 (2015).

Magi, A. et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol. 14, R120 (2013).

Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007–20012 (2007).

Ji, Z., Flaherty, K.T. & Tsao, H. Targeting the RAS pathway in melanoma. Trends Mol. Med. 18, 27–35 (2012).

Shibuya, M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb. Perspect. Biol. 5, a009092 (2013).

Johannessen, C.M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010).

Watson, I.R. et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 74, 4845–4852 (2014).

Newton, A.C. & Trotman, L.C. Turning off AKT: PHLPP as a drug target. Annu. Rev. Pharmacol. Toxicol. 54, 537–558 (2014).

Dong, L. et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene 33, 4756–4766 (2014).

Gallino, G. et al. Association between cutaneous melanoma and neurofibromatosis type 1: analysis of three clinical cases and review of the literature. Tumori 86, 70–74 (2000).

Seminog, O.O. & Goldacre, M.J. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br. J. Cancer 108, 193–198 (2013).

De Schepper, S. et al. Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. J. Invest. Dermatol. 128, 1050–1053 (2008).

Johnson, M.R., Look, A.T., DeClue, J.E., Valentine, M.B. & Lowy, D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc. Natl. Acad. Sci. USA 90, 5539–5543 (1993).

Andersen, L.B. et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat. Genet. 3, 118–121 (1993).

Marees, T. et al. Cancer mortality in long-term survivors of retinoblastoma. Eur. J. Cancer 45, 3245–3253 (2009).

Nyström, A.M. et al. A severe form of Noonan syndrome and autosomal dominant cafe-au-lait spots—evidence for different genetic origins. Acta Paediatr. 98, 693–698 (2009).

Prada, C.E. et al. Lethal presentation of neurofibromatosis and Noonan syndrome. Am. J. Med. Genet. A 155A, 1360–1366 (2011).

Thiel, C. et al. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am. J. Med. Genet. A 149A, 1263–1267 (2009).

Stites, E.C., Trampont, P.C., Haney, L.B., Walk, S.F. & Ravichandran, K.S. Cooperation between noncanonical Ras network mutations. Cell Rep. 10, 307–316 (2015).

Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190–200 (2010).

Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).